Annual report pursuant to Section 13 and 15(d)

Investment in Macrophage Therapeutics, Inc. (Details)

v3.3.1.900
Investment in Macrophage Therapeutics, Inc. (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Mar. 11, 2015
Mar. 31, 2015
Mar. 31, 2015
Dec. 31, 2015
Dec. 31, 2014
Schedule Of Investments [Line Items]          
Derivative liabilities       $ 63,000 $ 0
Deemed dividend on beneficial conversion feature of MT Preferred Stock       46,000  
Minimum required proceeds from initial public offering       $ 50,000,000  
Weighted average price per share       80.00%  
Price per share       $ 3.00  
Dr. Michael Goldberg [Member]          
Schedule Of Investments [Line Items]          
Percentage of preferred stock reserved   40.00% 40.00%    
Convertible Preferred Stock [Member]          
Schedule Of Investments [Line Items]          
Preferred stock authorized   50 50    
Purchase price per share (USD per share)   $ 50,000 $ 50,000    
Proceeds from issuance of convertible preferred stock and warrants $ 500,000        
Deemed dividend on beneficial conversion feature of MT Preferred Stock   $ 46,000      
Value of warrants       $ 2,000,000  
Put option fair value       113,000  
Common stock value       $ 50,000  
Macrophage Therapeutics [Member]          
Schedule Of Investments [Line Items]          
Shares authorized upon exercise of warrants   1,500 1,500    
Preferred shares, per unit     1    
Common stock warrants, per unit     30    
Macrophage Therapeutics [Member] | Convertible Preferred Stock [Member]          
Schedule Of Investments [Line Items]          
Preferred stock authorized   50 50    
Preferred stock issued 10        
Deemed dividend on beneficial conversion feature of MT Preferred Stock   $ 46,000      
Preferred stock value       $ 58,320  
Macrophage Therapeutics [Member] | Common Stock [Member]          
Schedule Of Investments [Line Items]          
Common stock as percentage of common equity   1.00% 1.00%    
Number of shares underlying warrant issued 300     300